

Supplementary Materials for
Transcriptional census of epithelial-mesenchymal plasticity in cancer

David P. Cook* and Barbara C. Vanderhyden

*Corresponding author. Email: david.cook@uottawa.ca (D.P.C.)

Published 5 January 2022, *Sci. Adv.* **8**, eabi7640 (2022)
DOI: 10.1126/sciadv.abi7640

The PDF file includes:

Legends for tables S1 and S2
Table S3
Figs. S1 to S7
References

Other Supplementary Material for this manuscript includes the following:

Tables S1 and S2


Table S1. A list of the most conserved genes associated with EMP among the 266 tumors analyzed.

Table S2. A refined list of conserved EMP genes, only including those from the signature whose expression is highly specific to malignant cells.


Cancer	Source	Accession	Platform	Sorted ?	Patient # (>100 malignant cells)	Total cancer cell #	% mitot threshold
Breast	Wu <i>et al.</i> (36)	ENA accession PRJEB35405	10x Genomics Chromium (3' v2)	NA	4	4452	20%
Breast	Qian <i>et al.</i> (28)	http://blueprint.lambrechtslab.org	10x Genomics Chromium (3')	NA	10	8766	20%
Breast	Bassez <i>et al.</i> (37)	http://biokey.lambrechtslab.org/	10x Genomics Chromium (5')	NA	62	38,765	15%
Colorectal	Lee <i>et al.</i> (26)	GEO Accession GSE144735 & GSE132465	10x Genomics Chromium (3' v2)	NA	25	18,058	20%
Colorectal	Uhlitz <i>et al.</i> (27)	Direct from authors	10x Genomics Chromium (3' v3)	NA	8	2659	20%
Colorectal	Qian <i>et al.</i> (28)	http://blueprint.lambrechtslab.org	10x Genomics Chromium (3')	NA	11	8766	25%
Gastric	Sathe <i>et al.</i> (29)	https://dna-discovery.stanford.edu	10x Genomics Chromium (3' v2)	NA	7	6909	20%
Lung	Kim <i>et al.</i> (32)	GEO Accession GSE131907	10x Genomics Chromium (3' v2)	NA	20	15,396	20%
Lung	Lambrechts <i>et al.</i> (31)	ArrayExpress Accessions E-MTAB-6149 & E-MTAB-6653	10x Genomics Chromium (3' v1/v2)	NA	9	8036	20%
Lung	Qian <i>et al.</i> (28)	http://blueprint.lambrechtslab.org	10x Genomics Chromium (3')	NA	24	6794	20%
Lung	Laughney <i>et al.</i> (24)	GEO Accession GSE123904	10x Genomics Chromium (3' v2)	Viability (scatter & DAPI)	8	3097	20%
Lung	Wu <i>et al.</i> (32)	GEO Accession GSE148071	GEXSCOPE (Singleron Biotechnologies)	NA	35	54,052	30%
Nasopharyngeal	Chen <i>et al.</i> (33)	GEO Accession GSE150430	10x Genomics Chromium (3' v2)	NA	9	7400	20%
Ovarian	Geistlinger <i>et al.</i> (34)	GEO Accession GSE154600	10x Genomics Chromium (3' v2)	NA	5	7479	20%
Ovarian	Qian <i>et al.</i> (28)	http://blueprint.lambrechtslab.org	10x Genomics Chromium (3')	NA	5	4967	20%
Pancreatic	Steele <i>et al.</i> (35)	GEO Accession GSE155698	10x Genomics Chromium (3')	NA	15	10,495	20%
Pancreatic	Peng <i>et al.</i> (53)	GSA: CRA001160	10x Genomics Chromium (3' v2)		24	41,986 (all cell types)	10%
Squamous cell carcinoma	Ji <i>et al.</i> (20)	GEO Accession GSE144236	10x Genomics Chromium (3' v2)	NA	9	12,154	10%

Table S3. Various metadata for the tumor scRNA-seq data analyzed.


Colorectal – Lee et al. (26)




Colorectal – KUL – Lee et al. (26)




Colorectal – Uhlitz et al. (27)




Colorectal – Qian et al. (28)



Gastric – Sathe et al. (29)










Figure S1. Processing pipeline for all 266 tumours. UMAP embeddings (left) of each data set showing hierarchical cluster, sample identity, and cell type identities of each cell. Cell type annotations were generated by automated annotation with singleR. Copy number alterations were predicted from the gene expression data of all cell types (right) and epithelial populations with genetic aberrations were classified as malignant cells.

Sample cell counts



Sample UMI counts



Percentage of mitochondrial UMIs per cell




Figure S2. Quality control metrics of all 266 tumours. Plots showing the number of malignant cells analyzed for each tumour, separated by study and cancer type. The distribution of total UMI counts and the percentage of mitochondrial UMIs per cell are also shown.




Figure S3. Variability of EMT gene sets. (A) UpSet plot showing the overlap of gene composition for 11 EMT gene sets (left) and plot showing the number of gene sets within which each gene occurs (right). (B) Pearson correlation coefficients of gene set UCell scores for each of the 11 EMT gene sets across the 266 tumours analyzed.




Figure S4. Characteristics of EMP programs. (A) Boxplot showing the distribution of Pearson correlation coefficients of sample-specific EMP program activity with the total number of UMIs and the percentage of mitochondrial UMIs per cell. (B) Clustered heatmap showing 78 genes from the conserved EMP signature whose expression has significant ($p < 0.05$, ANOVA) associations with specific cancers. (C) Plot showing genes most commonly downregulated with EMP program activity. Each point represents an individual gene downregulated in ≥ 10 EMP programs and colored points represent those downregulated more frequently than they are upregulated.





Figure S5. Association of canonical EMT genes with EMP programs. Top: Heatmap of EMP model coefficients for *VIM*, *SNAI1*, *SNAI2*, *ZEB1*, *CDH2*, and *TWIST1*. Bottom: Distribution of EMP model coefficients for each gene and expression values for programs with the highest coefficient for a given gene.






Figure S7. Identifying EMP signatures in cancer cell lines. (A) UMAP embedding of 99 cancer cell lines from the MIX-seq data set (60) (left) and pearson correlation coefficients of archetype activity scores and EMT gene set scores for all cells. (B) Same as (A), but for scRNA-seq data of A549, DU145, MCF7, and OVCA420 cells from Cook & Vanderhyden (8).

REFERENCES AND NOTES

1. J. Yang, P. Antin, G. Berx, C. Blanpain, T. Brabletz, M. Bronner, K. Campbell, A. Cano, J. Casanova, G. Christofori, S. Dedhar, R. Derynck, H. L. Ford, J. Fuxe, A. Garcia de Herreros, G. J. Goodall, A.-K. Hadjantonakis, R. J. Y. Huang, C. Kalchauer, R. Kalluri, Y. Kang, Y. Khew-Goodall, H. Levine, J. Liu, G. D. Longmore, S. A. Mani, J. Massagué, R. Mayor, D. McClay, K. E. Mostov, D. F. Newgreen, M. A. Nieto, A. Puisieux, R. Runyan, P. Savagner, B. Stanger, M. P. Stemmler, Y. Takahashi, M. Takeichi, E. Theveneau, J. P. Thiery, E. W. Thompson, R. A. Weinberg, E. D. Williams, J. Xing, B. P. Zhou, G. Sheng; EMT International Association (TEMTIA), Guidelines and definitions for research on epithelial-mesenchymal transition. *Nat. Rev. Mol. Cell Biol.* **21**, 341–352 (2020).
2. H. Gabbert, R. Wagner, R. Moll, C. D. Gerharz, Tumor dedifferentiation: An important step in tumor invasion. *Clin. Exp. Metastasis* **3**, 257–279 (1985).
3. S. V. Puram, I. Tirosh, A. S. Parikh, A. P. Patel, K. Yizhak, S. Gillespie, C. Rodman, C. L. Luo, E. A. Mroz, K. S. Emerick, D. G. Deschler, M. A. Varvares, R. Mylvaganam, O. Rozenblatt-Rosen, J. W. Rocco, W. C. Faquin, D. T. Lin, A. Regev, B. E. Bernstein, Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. *Cell* **171**, 1611–1624.e24 (2017).
4. A. Dongre, R. A. Weinberg, New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. *Nat. Rev. Mol. Cell Biol.* **20**, 69–84 (2019).
5. L. A. Horn, K. Fousek, C. Palena, Tumor plasticity and resistance to immunotherapy. *Trends Cancer Res.* **6**, 432–441 (2020).
6. V. Ramesh, T. Brabletz, P. Ceppi, Targeting EMT in cancer with repurposed metabolic inhibitors. *Trends Cancer* **6**, 942–950 (2020).
7. S. Bhatia, P. Wang, A. Toh, E. W. Thompson, New insights into the role of phenotypic plasticity and EMT in driving cancer progression. *Front. Mol. Biosci.* **7**, 71 (2020).
8. D. P. Cook, B. C. Vanderhyden, Context specificity of the EMT transcriptional response. *Nat. Commun.* **11**, 2142 (2020).
9. J. H. Taube, J. I. Herschkowitz, K. Komurov, A. Y. Zhou, S. Gupta, J. Yang, K. Hartwell, T. T. Onder, P. B. Gupta, K. W. Evans, B. G. Hollier, P. T. Ram, E. S. Lander, J. M. Rosen, R. A. Weinberg, S. A. Mani, Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 15449–15454 (2010).
10. P. Peixoto, A. Etcheverry, M. Aubry, A. Missey, C. Lachat, J. Perrard, E. Hendrick, R. Delage-Mourroux, J. Mosser, C. Borg, J.-P. Feugeas, M. Herfs, M. Boyer-Guittaut, E. Hervouet, EMT is associated with an epigenetic signature of ECM remodeling genes. *Cell Death Dis.* **10**, 205 (2019).

11. M. P. Stemmler, R. L. Eccles, S. Brabletz, T. Brabletz, Non-redundant functions of EMT transcription factors. *Nat. Cell Biol.* **21**, 102–112 (2019).
12. E. D. Williams, D. Gao, A. Redfern, E. W. Thompson, Controversies around epithelial-mesenchymal plasticity in cancer metastasis. *Nat. Rev. Cancer* **19**, 716–732 (2019).
13. K. R. Fischer, A. Durrans, S. Lee, J. Sheng, F. Li, S. T. C. Wong, H. Choi, T. El Rayes, S. Ryu, J. Troeger, R. F. Schwabe, L. T. Vahdat, N. K. Altorki, V. Mittal, D. Gao, Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. *Nature* **527**, 472–476 (2015).
14. X. Zheng, J. L. Carstens, J. Kim, M. Scheible, J. Kaye, H. Sugimoto, C.-C. Wu, V. S. LeBleu, R. Kalluri, Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. *Nature* **527**, 525–530 (2015).
15. N. M. Aiello, T. Brabletz, Y. Kang, M. A. Nieto, R. A. Weinberg, B. Z. Stanger, Upholding a role for EMT in pancreatic cancer metastasis. *Nature* **547**, E7–E8 (2017).
16. X. Ye, T. Brabletz, Y. Kang, G. D. Longmore, M. A. Nieto, B. Z. Stanger, J. Yang, R. A. Weinberg, Upholding a role for EMT in breast cancer metastasis. *Nature* **547**, E1–E3 (2017).
17. K. R. Fischer, N. K. Altorki, V. Mittal, D. Gao, Fischer et al. reply. *Nature* **547**, E5–E6 (2017).
18. E. Z. Macosko, A. Basu, R. Satija, J. Nemesh, K. Shekhar, M. Goldman, I. Tirosh, A. R. Bialas, N. Kamitaki, E. M. Martersteck, J. J. Trombetta, D. A. Weitz, J. R. Sanes, A. K. Shalek, A. Regev, S. A. McCarroll, Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. *Cell* **161**, 1202–1214 (2015).
19. A. M. Klein, L. Mazutis, I. Akartuna, N. Tallapragada, A. Veres, V. Li, L. Peshkin, D. A. Weitz, M. W. Kirschner, Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. *Cell* **161**, 1187–1201 (2015).
20. A. L. Ji, A. J. Rubin, K. Thrane, S. Jiang, D. L. Reynolds, R. M. Meyers, M. G. Guo, B. M. George, A. Mollbrink, J. Bergenstråhle, L. Larsson, Y. Bai, B. Zhu, A. Bhaduri, J. M. Meyers, X. Rovira-Clavé, S. T. Hollmig, S. Z. Aasi, G. P. Nolan, J. Lundeberg, P. A. Khavari, Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma. *Cell* **182**, 1661–1662 (2020).
21. A. Sharma, E. Y. Cao, V. Kumar, X. Zhang, H. S. Leong, A. M. L. Wong, N. Ramakrishnan, M. Hakimullah, H. M. V. Teo, F. T. Chong, S. Chia, M. T. Thangavelu, X. L. Kwang, R. Gupta, J. R. Clark, G. Periyasamy, N. Gopalakrishna Iyer, R. DasGupta, Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy. *Nat. Commun.* **9**, 4931 (2018).
22. S. Raghavan, P. S. Winter, A. W. Navia, H. L. Williams, A. DenAdel, R. L. Kalekar, J. Galvez-Reyes, K. E. Lowder, N. Mulugeta, M. S. Raghavan, A. A. Borah, S. A. Väyrynen, A. D. Costa, R. W. S. Ng, J. Wang, E. Reilly, D. Y. Ragon, L. K. Brais, A. M. Jaeger, L. F. Spurr, Y.

- Y. Li, A. D. Cherniack, I. Wakiro, A. Rotem, B. E. Johnson, J. M. McFarland, E. T. Sicinska, T. E. Jacks, T. E. Clancy, K. Perez, D. A. Rubinson, K. Ng, J. M. Cleary, L. Crawford, S. R. Manalis, J. A. Nowak, B. M. Wolpin, W. C. Hahn, A. J. Aguirre, A. K. Shalek, Transcriptional subtype-specific microenvironmental crosstalk and tumor cell plasticity in metastatic pancreatic cancer. doi:10.1101/2020.08.25.256214.
23. K. Ganesh, H. Basnet, Y. Kaygusuz, A. M. Laughney, L. He, R. Sharma, K. P. O'Rourke, V. P. Reuter, Y.-H. Huang, M. Turkecul, E. Emrah, I. Masilionis, K. Manova-Todorova, M. R. Weiser, L. B. Saltz, J. Garcia-Aguilar, R. Koche, S. W. Lowe, D. Pe'er, J. Shia, J. Massagué, L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. *Nat. Cancer*. **1**, 28–45 (2020).
24. A. M. Laughney, J. Hu, N. R. Campbell, S. F. Bakhoun, M. Setty, V.-P. Lavallée, Y. Xie, I. Masilionis, A. J. Carr, S. Kottapalli, V. Allaj, M. Mattar, N. Rekhman, J. B. Xavier, L. Mazutis, J. T. Poirier, C. M. Rudin, D. Pe'er, J. Massagué, Regenerative lineages and immune-mediated pruning in lung cancer metastasis. *Nat. Med.* **26**, 259–269 (2020).
25. G. S. Kinker, A. C. Greenwald, R. Tal, Z. Orlova, M. S. Cuoco, J. M. McFarland, A. Warren, C. Rodman, J. A. Roth, S. A. Bender, B. Kumar, J. W. Rocco, P. A. C. M. Fernandes, C. C. Mader, H. Keren-Shaul, A. Plotnikov, H. Barr, A. Tsherniak, O. Rozenblatt-Rosen, V. Krizhanovsky, S. V. Puram, A. Regev, I. Tirosh, Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity. *Nat. Genet.* **52**, 1208–1218 (2020).
26. H.-O. Lee, Y. Hong, H. E. Etlioglu, Y. B. Cho, V. Pomella, B. Van den Bosch, J. Vanhecke, S. Verbandt, H. Hong, J.-W. Min, N. Kim, H. H. Eum, J. Qian, B. Boeckx, D. Lambrechts, P. Tsantoulis, G. De Hertogh, W. Chung, T. Lee, M. An, H.-T. Shin, J.-G. Joung, M.-H. Jung, G. Ko, P. Wirapati, S. H. Kim, H. C. Kim, S. H. Yun, I. B. H. Tan, B. Ranjan, W. Y. Lee, T.-Y. Kim, J. K. Choi, Y.-J. Kim, S. Prabhakar, S. Tejpar, W.-Y. Park, Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. *Nat. Genet.* **52**, 594–603 (2020).
27. F. Uhlitz, P. Bischoff, S. Peidli, A. Sieber, B. Obermayer, E. Blanc, A. Trinks, M. Lüthen, Y. Ruchiy, T. Sell, S. Mamlouk, R. Arsie, T.-T. Wei, K. Klotz-Noack, R. F. Schwarz, B. Sawitzki, C. Kamphues, D. Beule, M. Landthaler, C. Sers, D. Horst, N. Blüthgen, M. Morkel, Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancer. *EMBO Mol. Med.* **13**, e14123 (2021).
28. J. Qian, S. Olbrecht, B. Boeckx, H. Vos, D. Laoui, E. Etlioglu, E. Wauters, V. Pomella, S. Verbandt, P. Busschaert, A. Bassez, A. Franken, M. V. Bempt, J. Xiong, B. Weynand, Y. van Herck, A. Antoranz, F. M. Bosisio, B. Thienpont, G. Floris, I. Vergote, A. Smeets, S. Tejpar, D. Lambrechts, A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. *Cell Res.* **30**, 745–762 (2020).
29. A. Sathe, S. M. Grimes, B. T. Lau, J. Chen, C. Suarez, R. J. Huang, G. Poultsides, H. P. Ji, Single-cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment. *Clin. Cancer Res.* **26**, 2640–2653 (2020).

30. D. Lambrechts, E. Wauters, B. Boeckx, S. Aibar, D. Nittner, O. Burton, A. Bassez, H. Decaluwé, A. Pircher, K. Van den Eynde, B. Weynand, E. Verbeken, P. De Leyn, A. Liston, J. Vansteenkiste, P. Carmeliet, S. Aerts, B. Thienpont, Phenotype molding of stromal cells in the lung tumor microenvironment. *Nat. Med.* **24**, 1277–1289 (2018).
31. N. Kim, H. K. Kim, K. Lee, Y. Hong, J. H. Cho, J. W. Choi, J.-I. Lee, Y.-L. Suh, B. M. Ku, H. H. Eum, S. Choi, Y.-L. Choi, J.-G. Joung, W.-Y. Park, H. A. Jung, J.-M. Sun, S.-H. Lee, J. S. Ahn, K. Park, M.-J. Ahn, H.-O. Lee, Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. *Nat. Commun.* **11**, 2285 (2020).
32. F. Wu, J. Fan, Y. He, A. Xiong, J. Yu, Y. Li, Y. Zhang, W. Zhao, F. Zhou, W. Li, J. Zhang, X. Zhang, M. Qiao, G. Gao, S. Chen, X. Chen, X. Li, L. Hou, C. Wu, C. Su, S. Ren, M. Odenthal, R. Buettner, N. Fang, C. Zhou, Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. *Nat. Commun.* **12**, 2540 (2021).
33. Y.-P. Chen, J.-H. Yin, W.-F. Li, H.-J. Li, D.-P. Chen, C.-J. Zhang, J.-W. Lv, Y.-Q. Wang, X.-M. Li, J.-Y. Li, P.-P. Zhang, Y.-Q. Li, Q.-M. He, X.-J. Yang, Y. Lei, L.-L. Tang, G.-Q. Zhou, Y.-P. Mao, C. Wei, K.-X. Xiong, H.-B. Zhang, S.-D. Zhu, Y. Hou, Y. Sun, M. Dean, I. Amit, K. Wu, D.-M. Kuang, G.-B. Li, N. Liu, J. Ma, Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. *Cell Res.* **30**, 1024–1042 (2020).
34. L. Geistlinger, S. Oh, M. Ramos, L. Schiffer, R. S. LaRue, C. M. Henzler, S. A. Munro, C. Daughters, A. C. Nelson, B. J. Winterhoff, Z. Chang, S. Talukdar, M. Shetty, S. A. Mullany, M. Morgan, G. Parmigiani, M. J. Birrer, L.-X. Qin, M. Riester, T. K. Starr, L. Waldron, Multiomic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma. *Cancer Res.* **80**, 4335–4345 (2020).
35. N. G. Steele, E. S. Carpenter, S. B. Kemp, V. R. Sirihorachai, S. The, L. Delrosario, J. Lazarus, E.-A. D. Amir, V. Gunchick, C. Espinoza, S. Bell, L. Harris, F. Lima, V. Irizarry-Negron, D. Paglia, J. Macchia, A. K. Y. Chu, H. Schofield, E.-J. Wamsteker, R. Kwon, A. Schulman, A. Prabhu, R. Law, A. Sondhi, J. Yu, A. Patel, K. Donahue, H. Nathan, C. Cho, M. A. Anderson, cV. Sahai, C. A. Lyssiotis, W. Zou, B. L. Allen, A. Rao, H. C. Crawford, F. Bednar, T. L. Frankel, M. P. di Magliano, Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. *Nat. Cancer.* **1**, 1097–1112 (2020).
36. S. Z. Wu, D. L. Roden, C. Wang, H. Holliday, K. Harvey, A. S. Cazet, K. J. Murphy, B. Pereira, G. Al-Eryani, N. Bartonicek, R. Hou, J. R. Torpy, S. Junankar, C.-L. Chan, C. E. Lam, M. N. Hui, L. Gluch, J. Beith, A. Parker, E. Robbins, D. Segara, C. Mak, C. Cooper, S. Warrior, A. Forrest, J. Powell, S. O’Toole, T. R. Cox, P. Timpson, E. Lim, X. S. Liu, A. Swarbrick, Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. *EMBO J.* **39**, e104063 (2020).
37. A. Bassez, H. Vos, L. Van Dyck, G. Floris, I. Arijs, C. Desmedt, B. Boeckx, M. Vanden Bempt, I. Nevelsteen, K. Lambein, K. Punie, P. Neven, A. D. Garg, H. Wildiers, J. Qian, A.

- Smeets, D. Lambrechts, A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. *Nat. Med.* **27**, 820–832 (2021).
38. A. Liberzon, C. Birger, H. Thorvaldsdóttir, M. Ghandi, J. P. Mesirov, P. Tamayo, The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst.* **1**, 417–425 (2015).
39. H. Yuan, M. Yan, G. Zhang, W. Liu, C. Deng, G. Liao, L. Xu, T. Luo, H. Yan, Z. Long, A. Shi, T. Zhao, Y. Xiao, X. Li, CancerSEA: A cancer single-cell state atlas. *Nucleic Acids Res.* **47**, D900–D908 (2019).
40. M. Zhao, L. Kong, Y. Liu, H. Qu, dbEMT: An epithelial-mesenchymal transition associated gene resource. *Sci. Rep.* **5**, 11459 (2015).
41. T. Z. Tan, Q. H. Miow, Y. Miki, T. Noda, S. Mori, R. Y.-J. Huang, J. P. Thiery, Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. *EMBO Mol. Med.* **6**, 1279–1293 (2014).
42. S. Mohammadi, J. Davila-Velderrain, M. Kellis, A multiresolution framework to characterize single-cell state landscapes. *Nat. Commun.* **11**, 5399 (2020).
43. I. Pastushenko, A. Brisebarre, A. Sifrim, M. Fioramonti, T. Revenco, S. Boumahdi, A. Van Keymeulen, D. Brown, V. Moers, S. Lemaire, S. De Clercq, E. Minguijón, C. Balsat, Y. Sokolow, C. Dubois, F. De Cock, S. Scozzaro, F. Sopena, A. Lanas, N. D’Haene, I. Salmon, J.-C. Marine, T. Voet, P. A. Sotiropoulou, C. Blanpain, Identification of the tumour transition states occurring during EMT. *Nature* **556**, 463–468 (2018).
44. C. Kröger, A. Afeyan, J. Mraz, E. N. Eaton, F. Reinhardt, Y. L. Khodor, P. Thiru, B. Bierie, X. Ye, C. B. Burge, R. A. Weinberg, Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 7353–7362 (2019).
45. I. Pastushenko, C. Blanpain, EMT transition states during tumor progression and metastasis. *Trends Cell Biol.* **29**, 212–226 (2019).
46. K. Williams, R. Ghosh, P. V. Giridhar, G. Gu, T. Case, S. M. Belcher, S. Kasper, Inhibition of stathmin1 accelerates the metastatic process. *Cancer Res.* **72**, 5407–5417 (2012).
47. M. A. B. Rosales, D. Y. Shu, J. Iacovelli, M. Saint-Geniez, Loss of PGC-1 α in RPE induces mesenchymal transition and promotes retinal degeneration. *Life Sci. Alliance* **2**, e201800212 (2019).
48. J. H. Tsai, J. Yang, Epithelial-mesenchymal plasticity in carcinoma metastasis. *Genes Dev.* **27**, 2192–2206 (2013).
49. N. M. Aiello, R. Maddipati, R. J. Norgard, D. Balli, J. Li, S. Yuan, T. Yamazoe, T. Black, A. Sahmoud, E. E. Furth, D. Bar-Sagi, B. Z. Stanger, EMT subtype influences epithelial plasticity and mode of cell migration. *Dev. Cell.* **45**, 681–695.e4 (2018).

50. B. Izar, I. Tirosh, E. H. Stover, I. Wakiro, M. S. Cuoco, I. Alter, C. Rodman, R. Leeson, M.-J. Su, P. Shah, M. Iwanicki, S. R. Walker, A. Kanodia, J. C. Melms, S. Mei, J.-R. Lin, C. B. M. Porter, M. Slyper, J. Waldman, L. Jerby-Arnon, O. Ashenberg, T. J. Brinker, C. Mills, M. Rogava, S. Vigneau, P. K. Sorger, L. A. Garraway, P. A. Konstantinopoulos, J. F. Liu, U. Matulonis, B. E. Johnson, O. Rozenblatt-Rosen, A. Rotem, A. Regev, A single-cell landscape of high-grade serous ovarian cancer. *Nat. Med.* **26**, 1271–1279 (2020).
51. C. Isella, A. Terrasi, S. E. Bellomo, C. Petti, G. Galatola, A. Muratore, A. Mellano, R. Senetta, A. Cassenti, C. Sonetto, G. Inghirami, L. Trusolino, Z. Fekete, M. De Ridder, P. Cassoni, G. Storme, A. Bertotti, E. Medico, Stromal contribution to the colorectal cancer transcriptome. *Nat. Genet.* **47**, 312–319 (2015).
52. M. Tyler, I. Tirosh, Decoupling epithelial-mesenchymal transitions from stromal profiles by integrative expression analysis. *Nat. Commun.* **12**, 2592 (2021).
53. J. Peng, B.-F. Sun, C.-Y. Chen, J.-Y. Zhou, Y.-S. Chen, H. Chen, L. Liu, D. Huang, J. Jiang, G.-S. Cui, Y. Yang, W. Wang, D. Guo, M. Dai, J. Guo, T. Zhang, Q. Liao, Y. Liu, Y.-L. Zhao, D.-L. Han, Y. Zhao, Y.-G. Yang, W. Wu, Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. *Cell Res.* **29**, 725–738 (2019).
54. K. A. Hoadley, C. Yau, T. Hinoue, D. M. Wolf, A. J. Lazar, E. Drill, R. Shen, A. M. Taylor, A. D. Cherniack, V. Thorsson, R. Akbani, R. Bowlby, C. K. Wong, M. Wiznerowicz, F. Sanchez-Vega, A. G. Robertson, B. G. Schneider, M. S. Lawrence, H. Noushmehr, T. M. Malta; Cancer Genome Atlas Network, J. M. Stuart, C. C. Benz, P. W. Laird, Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. *Cell* **173**, 291–304.e6 (2018).
55. V. Thorsson, D. L. Gibbs, S. D. Brown, D. Wolf, D. S. Bortone, T.-H. O. Yang, E. Porta-Pardo, G. F. Gao, C. L. Plaisier, J. A. Eddy, E. Ziv, A. C. Culhane, E. O. Paull, I. K. A. Sivakumar, A. J. Gentles, R. Malhotra, F. Farshidfar, A. Colaprico, J. S. Parker, L. E. Mose, N. S. Vo, J. Liu, Y. Liu, J. Rader, V. Dhankani, S. M. Reynolds, R. Bowlby, A. Califano, A. D. Cherniack, D. Anastassiou, D. Bedognetti, Y. Mokrab, A. M. Newman, A. Rao, K. Chen, A. Krasnitz, H. Hu, T. M. Malta, H. Noushmehr, C. S. Pdamallu, S. Bullman, A. I. Ojesina, A. Lamb, W. Zhou, H. Shen, T. K. Choueiri, J. N. Weinstein, J. Guinney, J. Saltz, R. A. Holt, C. S. Rabkin; Cancer Genome Atlas Research Network, A. J. Lazar, J. S. Serody, E. G. Demicco, M. L. Disis, B. G. Vincent, I. Shmulevich, The immune landscape of cancer. *Immunity* **48**, 812–830.e14 (2018).
56. R. Browaeys, W. Saelens, Y. Saeys, NicheNet: Modeling intercellular communication by linking ligands to target genes. *Nat. Methods* **17**, 159–162 (2020).
57. M. Schubert, B. Klinger, M. Klünemann, A. Sieber, F. Uhlitz, S. Sauer, M. J. Garnett, N. Blüthgen, J. Saez-Rodriguez, Perturbation-response genes reveal signaling footprints in cancer gene expression. *Nat. Commun.* **9**, 20 (2018).

58. J. Cursons, K.-J. Leuchowius, M. Waltham, E. Tomaskovic-Crook, M. Foroutan, C. P. Bracken, A. Redfern, E. J. Crampin, I. Street, M. J. Davis, E. W. Thompson, Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. *Cell Commun. Signal.* **13**, 26 (2015).
59. S. Aibar, C. B. González-Blas, T. Moerman, V. A. Huynh-Thu, H. Imrichova, G. Hulselmans, F. Rambow, J.-C. Marine, P. Geurts, J. Aerts, J. van den Oord, Z. K. Atak, J. Wouters, S. Aerts, SCENIC: Single-cell regulatory network inference and clustering. *Nat. Methods* **14**, 1083–1086 (2017).
60. J. M. McFarland, B. R. Paoletta, A. Warren, K. Geiger-Schuller, T. Shibue, M. Rothberg, O. Kuksenko, W. N. Colgan, A. Jones, E. Chambers, D. Dionne, S. Bender, B. M. Wolpin, M. Ghandi, I. Tirosh, O. Rozenblatt-Rosen, J. A. Roth, T. R. Golub, A. Regev, A. J. Aguirre, F. Vazquez, A. Tsherniak, Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. *Nat. Commun.* **11**, 4296 (2020).
61. J. L. McFaline-Figueroa, A. J. Hill, X. Qiu, D. Jackson, J. Shendure, C. Trapnell, A pooled single-cell genetic screen identifies regulatory checkpoints in the continuum of the epithelial-to-mesenchymal transition. *Nat. Genet.* **51**, 1389–1398 (2019).
62. M. A. Nieto, R. Y.-J. Huang, R. A. Jackson, J. P. Thiery, EMT: 2016. *Cell* **166**, 21–45 (2016).
3. S. Zadran, R. Arumugam, H. Herschman, M. E. Phelps, R. D. Levine, Surprisal analysis characterizes the free energy time course of cancer cells undergoing epithelial-to-mesenchymal transition. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 13235–13240 (2014).
64. D. Jia, M. K. Jolly, S. C. Tripathi, P. Den Hollander, B. Huang, M. Lu, M. Celikbas, E. Ramirez-Peña, E. Ben-Jacob, J. N. Onuchic, S. M. Hanash, S. A. Mani, H. Levine, Distinguishing mechanisms underlying EMT tristability. *Cancer Conver.* **1**, 2 (2017).
65. Y. Hao, S. Hao, E. Andersen-Nissen, W. M. Mauck, S. Zheng, A. Butler, M. J. Lee, A. J. Wilk, C. Darby, M. Zagar, P. Hoffman, M. Stoeckius, E. Papalexi, E. P. Mimitou, J. Jain, A. Srivastava, T. Stuart, L. B. Fleming, B. Yeung, A. J. Rogers, J. M. McElrath, C. A. Blish, R. Gottardo, P. Smibert, R. Satija, Integrated analysis of multimodal single-cell data. *bioRxiv*, 2020.10.12.335331 (2020).
66. D. Aran, A. P. Looney, L. Liu, E. Wu, V. Fong, A. Hsu, S. Chak, R. P. Naikawadi, P. J. Wolters, A. R. Abate, A. J. Butte, M. Bhattacharya, Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat. Immunol.* **20**, 163–172 (2019).
67. M. Andreatta, S. J. Carmona, UCell: Robust and scalable single-cell gene signature scoring. *Comput. Struct. Biotechnol. J.* **19**, 3796–3798 (2021).
68. M. M. Ibrahim, R. Kramann, genesorteR: Feature ranking in clustered single cell data. *bioRxiv* 676379 (2019).

69. D. Aran, M. Sirota, A. J. Butte, Systematic pan-cancer analysis of tumour purity. *Nat. Commun.* **6**, 8971 (2015).
70. V. Thorsson, D. L. Gibbs, S. D. Brown, D. Wolf, D. S. Bortone, T.-H. O. Yang, E. Porta-Pardo, G. F. Gao, C. L. Plaisier, J. A. Eddy, E. Ziv, A. C. Culhane, E. O. Paull, I. K. A. Sivakumar, A. J. Gentles, R. Malhotra, F. Farshidfar, A. Colaprico, J. S. Parker, L. E. Mose, N. S. Vo, J. Liu, Y. Liu, J. Rader, V. Dhankani, S. M. Reynolds, R. Bowlby, A. Califano, A. D. Cherniack, D. Anastassiou, D. Bedognetti, Y. Mokrab, A. M. Newman, A. Rao, K. Chen, A. Krasnitz, H. Hu, T. M. Malta, H. Noushmehr, C. S. Pedomallu, S. Bullman, A. I. Ojesina, A. Lamb, W. Zhou, H. Shen, T. K. Choueiri, J. N. Weinstein, J. Guinney, J. Saltz, R. A. Holt, C. S. Rabkin; Cancer Genome Atlas Research Network, A. J. Lazar, J. S. Serody, E. G. Demicco, M. L. Disis, B. G. Vincent, I. Shmulevich, The immune landscape of cancer. *Immunity* **51**, 411–412 (2019).
71. C. H. Holland, B. Szalai, J. Saez-Rodriguez, Transfer of regulatory knowledge from human to mouse for functional genomics analysis. *Biochim. Biophys. Acta Gene Regul. Mech.* **1863**, 194431 (2020).
72. C. H. Holland, J. Tanevski, J. Perales-Patón, J. Gleixner, M. P. Kumar, E. Mereu, B. A. Joughin, O. Stegle, D. A. Lauffenburger, H. Heyn, B. Szalai, J. Saez-Rodriguez, Robustness and applicability of transcription factor and pathway analysis tools on single-cell RNA-seq data. *Genome Biol.* **21**, 36 (2020).